160
Participants
Start Date
February 23, 2021
Primary Completion Date
January 27, 2025
Study Completion Date
October 25, 2025
Pembrolizumab
Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
Lenvatinib
Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304), Budapest
Macquarie University-MQ Health Clinical Trials Unit ( Site 0405), Macquarie Park
Calvary Mater Newcastle ( Site 0403), Waratah
Monash Health ( Site 0400), Clayton
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C, Miskolc
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si, Brisbane
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300), Debrecen
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303), Szolnok
Ashford Cancer Centre Research ( Site 0404), Kurralta Park
Fiona Stanley Hospital ( Site 0402), Murdoch
Memorial Sloan Kettering Cancer Center ( Site 0015), New York
Chernihiv Medical Center of Modern Oncology ( Site 0509), Chernihiv
Centre François Baclesse ( Site 1000), Caen
Cherkasy Regional Oncology Dispensary ( Site 0504), Cherkassy
Fox Chase Cancer Center ( Site 0011), Philadelphia
Georgetown University Medical Center ( Site 0001), Washington D.C.
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903), Milan
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0200), Madrid
Centre de Cancérologie du Grand Montpellier ( Site 1005), Montpellier
Istanbul Universitesi Cerrahpasa ( Site 1104), Istanbul- Fatih
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1103), Istanbul
Ege University Medicine of Faculty ( Site 1102), Bornova
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902), Verona
Vanderbilt University Medical Center ( Site 0008), Nashville
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0202), Valencia
Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 0508), Dnipro
MEDICAL COLLEGE OF WISCONSIN ( Site 0006), Milwaukee
St. Vincent Frontier Cancer Center ( Site 0004), Billings
"CNPE Regional Center of Oncology-oncourology department ( Site 0502)", Kharkiv
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007), Strasbourg
centre hospitalier lyon sud ( Site 1003), Pierre-Bénite
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas
Gustave Roussy ( Site 1002), Villejuif
Seattle Cancer Care Alliance ( Site 0014), Seattle
Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602), Moscow
SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607), Saint Petersburg
Volga District Medical Center-Urology Department ( Site 0604), Nizhny Novgorod
Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605), Nizhny Novgorod
BC Cancer Vancouver-Clinical Trials Unit ( Site 1500), Vancouver
Sunnybrook Health Sciences Centre ( Site 1501), Toronto
Princess Margaret Cancer Centre ( Site 1504), Toronto
CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502), Québec
Tallaght University Hospital ( Site 1600), Dublin
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901), Rome
Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900), Terni
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800), Poznan
Luxmed Onkologia sp. z o. o. ( Site 0802), Warsaw
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warsaw
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302), Seoul
Asan Medical Center-Department of Oncology ( Site 1300), Seoul
Samsung Medical Center ( Site 1301), Seoul
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0201), Barcelona
Ankara University Hospital Cebeci ( Site 1105), Ankara
Hacettepe Universitesi-oncology hospital ( Site 1101), Ankara
Cambridge University Hospital ( Site 1200), Cambridge
The Christie ( Site 1205), Manchester
Eisai Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY